Nielsen, L. K., Stege, C., Lissenberg-Witte, B., van der Holt, B., Mellqvist, U.-H., Salomo, M., Bos, G., Levin, M.-D., Visser-Wisselaar, H., Hansson, M., van der Velden, A., Deenik, W., Coenen, J., Hinge, M., Klein, S., Tanis, B., Szatkowski, D., Brouwer, R., Westerman, M., Leys, R., Sinnige, H., Haukås, E., van der Hem, K., Durian, M., Gimsing, P., van de Donk, N., Sonneveld, P., Waage, A., Abildgaard, N. and Zweegman, S. (2020) “Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study”, Haematologica. Pavia, Italy, 105(6), pp. 1650-1659. doi: 10.3324/haematol.2019.222299.